

Research article

Open Access

Evaluation of arthroscopy and macroscopic scoring

Erik af Klint, Anca I Catrina, Peter Matt, Petra Neregråd, Jon Lampa, Ann-Kristin Ulfgren, Lars Klareskog and Staffan Lindblad

Rheumatology Unit, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, Building D2:01, S-171 76 Stockholm, Sweden

Corresponding author: Erik af Klint, erik.af.klint@ki.se

Received: 14 May 2007 Revisions requested: 4 Jun 2007 Revisions received: 4 May 2009 Accepted: 2 Jun 2009 Published: 2 Jun 2009

Arthritis Research & Therapy 2009, 11:R81 (doi:10.1186/ar2714)This article is online at: <http://arthritis-research.com/content/11/3/R81>© 2009 af Klint *et al.*; licensee BioMed Central Ltd.This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.**Abstract**

Introduction Arthroscopy is a minimally invasive technique for retrieving synovial biopsies in rheumatology during the past 20 years. Vital for its use is continual evaluation of its safety and efficacy. Important for sampling is the fact of intraarticular variation for synovial markers. For microscopic measurements scoring systems have been developed and validated, but for macroscopic evaluations there is a need for further comprehensive description and validation of equivalent scoring systems.

Methods We studied the complication rate and yield of arthroscopies performed at our clinic between 1998 and 2005. We also created and evaluated a macroscopic score set of instructions for synovitis.

Results Of 408 procedures, we had two major and one minor complication; two haemarthrosis and one wound infection, respectively. Pain was most often not a problem, but 12 procedures had to be prematurely ended due to pain. Yield of

biopsies adequate for histology were 83% over all, 94% for knee joints and 34% for smaller joints. Video printer photographs of synovium taken during arthroscopy were jointly and individually reviewed by seven raters in several settings, and intra and inter rater variation was calculated. A macroscopic synovial scoring system for arthroscopy was created (Macro-score), based upon hypertrophy, vascularity and global synovitis. These written instructions were evaluated by five control-raters, and when evaluated individual parameters were without greater intra or inter rater variability, indicating that the score is reliable and easy to use.

Conclusions In our hands rheumatologic arthroscopy is a safe method with very few complications. For knee joints it is a reliable method to retrieve representative tissue in clinical longitudinal studies. We also created an easy to use macroscopic score, that needs to be validated against other methodologies. We hope it will be of value in further developing international standards in this area.

Introduction

Diseases causing chronic inflammation in joints are common and often debilitating conditions. The synovial membrane (SM) is the primary target organ for the immune system in many chronic arthritides, and particularly in rheumatoid arthritis (RA) where a pannus of cells is formed, eroding cartilage and bone. Consequently, it is to be expected that investigations of the SM will provide clues to the pathogenesis of disease and effect of therapy. A number of studies have shown that the inflammatory changes in the synovium correlate with clinical [1-6], as well as radiological [7-10], outcomes.

Effects of different treatments [11-32] on these patterns have been studied and efforts have been made to investigate

whether synovial histology markers could be used to evaluate the effect of a drug with some success [27,30,32]. Sampling of the synovial membrane has also been used as a 'proof of concept' prior to [33] or early on in clinical trials [34] of new drugs. Importantly, more recent studies have also found predictive markers of clinical effect [28,31,35]; however, more work needs to be conducted before we have simple markers enabling physicians to individually tailor medication. So far these markers are exclusively present in the synovium, the target organ of the inflammation, requiring surgical sampling of tissue.

Arthroscopy is a minimally invasive technique, traditionally used by orthopaedic surgeons, which has evolved as a

H&E: haematoxylin and eosin; RA: rheumatoid arthritis; SM: synovial membrane.

research instrument in rheumatology to permit retrieval of SM during the past 20 years. Vital for its use is continual evaluation of its safety and efficacy, and the fact that there is intra-articular variation for synovial markers is important for sampling [36]. For microscopic measurements scoring systems have been developed and validated [37,38], but for macroscopic evaluations there is a need for further comprehensive description and validation of equivalent scoring systems.

In this report we aim to document our own experience with arthroscopy [36,39-51] describing the method, its safety and evaluating a macroscopic scoring system of synovitis developed by us.

Materials and methods

Patients

For seven years, from September 1999 to September 2005, 234 patients were recruited from the rheumatology clinic at the Karolinska University Hospital, and three patients from private rheumatologists. For research purposes, 210 patients were recruited, and 27 patients were recruited for clinical routine examination. Except for 10 healthy individuals, all patients had clinically active arthritis or joint pain at the time of arthroscopy. Indications for arthroscopy in clinical routine practice were mainly arthritis of unknown origin (mainly monoarthritis) or arthritis in singular joints without satisfying response to therapy. Projects for research purposes were primarily aimed at learning more about the early course of disease and the molecular mode of action of different anti-rheumatic treatments. Contraindications for arthroscopy were age below 18 years, prosthesis, clotting or bleeding deficiency, known allergy to local anaesthetics and cases where we were unable to communicate appropriately with the patient for psychological reasons or for language difficulties. Further, we did not include patients with septic arthritis, haemarthrosis, joint trauma or mechanical joint complications.

Methods


All arthroscopies were performed in the same procedure room, designated for this and other small operative procedures requiring sterility and situated at our outpatient clinic. During most procedures three or more persons were involved; one or two operators (one teaching), one nurse and one assistant nurse (not in sterile dressing) taking care of tissue samples. Rod-lens arthroscopes (Karl Storz GmbH, Tuttlingen, Germany) of three different dimensions (1.9 mm for proximal interphalangeal, metacarpophalangeal, wrist and elbow joints; 2.4 mm for shoulder, ankle and knee joints, and 4.0 mm for knee joints), all with a 30° angle, were used throughout. Spoon forceps (Karl Storz GmbH, Tuttlingen, Germany) of different sizes were used to obtain the biopsies, the largest with a diameter of 3.5 mm, was used in knee joints. To minimise the effects of the procedure on the macroscopic appearance of the SM including circulation, no tourniquet was used, anaesthetic drug (xylocain) was used without adrenaline and maxi-

um water pressure was put at 50 cm (for irrigation fluid). All arthroscopies were performed in accordance with the Helsinki Declaration, and where appropriate, ethical permission was given by the ethical committee at the Karolinska Institute, and written consent given by each patient before entering study.

Biopsies were put in cryotubes (Simport Plastics, Quebec, Canada) and frozen in precooled (-70°C) isopentane within two minutes (most often within one minute) after removal. They were stored until sectioned in -70°C. Before sectioning, biopsies were embedded in Tissue-Tek® O.C.T. Compound (Sakura Finetek USA Inc, Torrance, California, USA). All biopsies were cut in -20°C (cryostat setting; 7 µm) and stained with H&E in a standard procedure. The sections were evaluated for adequate histology (inflammation and not subsynovial or fibrotic tissue) before further stainings were performed.

The arthroscopic procedure of the knee joint is detailed below, and is principally the same for other joints. The joint is examined from the outside for signs of inflammation (pain, swelling and hypertrophy of the joint capsule). Two entry portals are then localised (infralateral, supralateral and/or supramedial portals) and anaesthetised using 10 to 15 ml of xylocaine 10 mg/ml without adrenaline for skin and joint capsule. Disinfection and draping of the leg occurs. A minimal skin incision is made with a scalpel (<5 mm) for portals. The arthroscope portal and trocar are introduced and excessive synovial fluid is extracted and stored. The trocar is replaced by the arthroscope, and 10 ml of xylocaine is added in to the joint as it is filled with physiological saline for clear vision. The synovium is inspected systematically (suprapatellar pouch, lateral and medial recesses and gutters, leaving the tibiofemoral joint and posterior cavity of the joint). Water pressure is kept below 30 cm, so as not to interfere with vascularity. Biopsy sites are chosen according to maximal macroscopic inflammation and anatomical site (preferably three sites; one close to the cartilage-pannus-junction and two further away), and photographed.

The second portal for the biopsy forceps is then introduced. Synovial biopsies are retrieved, six to eight from each site, 12 to 24 per joint in total. Care is taken not to sample too deeply (subsynovial fat or capsule). Maximum time from biopsy sampling to freezing is set at two minutes, but is usually within 30 to 40 seconds. Joint lavage, to remove blood and debris, is used when needed for visibility throughout the procedure, but kept at a minimum so as not to interfere with treatment effect for drug evaluation (usually 300 to 600 ml, and never more than 1000 ml). Excessive fluid is extracted from the joint via both portals and intraarticular steroids are introduced via the arthroscope if indicated. Portals are removed, wounds cleaned, dried and taped with sterile strips then covered with sterile waterproof dressing. Immediately after the arthroscopy the operator maps the biopsy sites, as well as areas of increased vascularity, hypertrophy (granulations and villi) and fibrosis [36]. The map (Figure 1), together with the photo-

Figure 1

Arthroscopy map of the knee joints. The patella is folded sideways. Areas of hypertrophy (villi, granulations) are marked as indicated, areas of increased vascularity are encircled and biopsy sites are mapped immediately following each procedure by the performing arthroscopist. Dx, right side of patient; SIN, left side of patient.

graphs taken, makes it possible to resample in close proximity to the primary site during consecutive procedures. The map and photos also allow retrospective analysis of biopsy sites and activity.

The entire procedure normally takes 40 to 60 minutes, and because only local anaesthetics and no sedation is used, the patient is able to walk immediately after the procedure. Before leaving the clinic, the patient is informed to avoid water contact on the wounds for two days. In order to quantitate possible complications and help patients after the procedure, the patient is contacted by the rheumatologist who performed the arthroscopy within the next few days. The occurrence of any complications is registered immediately after the arthroscopic procedure, at the following telephone contact and at consecutive contacts with the patients.

Creation and evaluation of a macroscopic scoring system

Eight representative video printer photographs, taken at knee joint arthroscopy procedures, were chosen by one of the authors (EaK) to illustrate various features of macroscopic synovitis and serve as reference images. Scoring was made by EaK in relation to three parameters; hypertrophy, vascularity and synovitis. For each parameter a five point scale (0 to 4) was used.

Seven raters (rater 1 to rater 7) with different experience in arthroscopy were asked to score 50 different joint images that had been selected by EaK, after the scale had been described to each rater by EaK. The order of reading was randomised.

All scores were collected and inter-individual variation registered. Images that produced very variable scores were re-evaluated during a joint session. The eight reference image scores used were revised together. Ten new images were scored by

all observers individually. These scores were compared, and a reference score was decided for each of these images.

From the experience gained in this study we prepared instructions for macroscopic scoring including characterised arthroscopic images, the 'Macro-score' [see Additional data files 1 and 2]. A new set of 50 images were scored by all raters at two occasions, with a minimum of 24 hours in between. The scores were analysed by descriptive analysis, including intra- and inter-rater variability and median scores.

Five control-raters with no previous experience of arthroscopy scored the same set of 50 images. They did not receive any further instructions than the Macro-score written instructions. Control-rater scores were analysed by descriptive statistics, including inter-rater variability and comparison to the median scores.

Results

Evaluation of the arthroscopic procedure for feasibility, complications and for yield of biopsies suitable for analysis

During seven years we performed 408 arthroscopic procedures in 237 patients (Tables 1 and 2 for patient characteristics). Two out of three of the patients were classified as RA, fulfilling the American College of Rheumatology criteria [52]. The mean disease duration was 7.5 years (median 4 years) and 32% had disease duration less than one year. The mean arthritis duration was 43 weeks (median 12 weeks) and 72% were women. The maximum number of arthroscopies performed in one patient was four (six patients). The procedure itself typically lasted 40 to 60 minutes, with the most time required for preparation (disinfection, anaesthesia, draping etc). In a limited number of procedures ($n = 38$) only the operator and the assistant nurse were involved, showing the feasibility of this simplified approach.

Table 1

Patient characteristics at time of arthroscopy	
Number of procedures	408
Number of patients	237
Age (mean)	52 years (range 20 to 85)
Sex	170 women/67 men
Disease duration (mean)	91 months (range 1 to 623)
Arthritis duration (mean)	43.5 weeks (range 0 to 564)
Patients on NSAIDs at arthroscopy	148
Patients on DMARDs at arthroscopy	99 (88 on methotrexate)

DMARDs = disease-modifying anti-rheumatic drugs; NSAIDs = non-steroidal anti-inflammatory drugs.

Except for two patients presenting with haemarthrosis three days and two weeks after the arthroscopy, respectively, no major complications were seen including deep vein thrombosis. A minor complication was one wound infection six weeks after arthroscopy at the supralateral portal where the patient had not removed the surgical strips. Intraarticular bleeding during the procedure could complicate biopsy sampling due to loss of vision, especially in small joints. However, in all of

these cases bleeding stopped during or soon after the procedure. Pain in the investigated or other joint occurred in a small number of patients and in 12 (3%) cases pain restricted the procedure so that no or fewer biopsies were taken than were originally planned. In one patient pain was considered severe two weeks after the procedure. Additional medical treatment was received and the pain subsided slowly. In one patient the joint was not extending due to an inability to relax, requiring the arthroscopy to be terminated. In 18 procedures (11 knee joints and 7 small or medium-sized joints) we abstained from biopsies as no active synovitis could be visualised. In these cases synovium was either normal or fibrotic as assessed macroscopically. No patient had to stay at the hospital for more than one hour after the procedure, and no long-term complications were seen.

For knee arthroscopies, 97% of procedures were conducted as planned, and 95% of retrieved tissue was appropriate for histology, resulting in a total yield of 92% (Table 3). For smaller joints the quality of the biopsies was less consistent, resulting in 86% of the arthroscopies to be conducted as planned, with 40% of the retrieved tissue being appropriate for histology, resulting in a total yield of appropriate biopsy material of 34%. The major reason for this low yield in small joints was the diffi-

Table 2

Diagnosis	All patients (n)	RF+ (n)	Patients with early disease (<12 months) (n)	RF+ (n)
Rheumatoid arthritis	160	129	52	39
Undifferentiated monoarthritis	13	4/11 ^a	8 ^b	2/6 ^a
Undifferentiated oligoarthritis	9	2	4 ^b	1
Undifferentiated polyarthritis	7	2	5 ^c	1
Juvenile idiopathic arthritis	9	4	0	0
Adult Still's disease	1	0	0	0
Undifferentiated spondylarthritis	4	0	2	0
Psoriatic arthritis	12	0	2	0
Ankylosing spondylitis	1	0	0	0
Ulcerative colitis	2	0/1 ^d	1	0
Undifferentiated systemic inflammatory disease with arthritis	1	0	0	0
Systemic lupus erythematosus	3	0	1	0
Cutaneous PAN with arthritis	1	0	0	0
Osteoarthritis	4	4	1	1
Healthy individuals	10	ND	NA	NA
Sum	237	141	76	42

All patients had clinically active inflammation or pain in at least the investigated joint (exceptions: healthy individuals). ^a Two patients were not tested for RF. ^b One RF+ patient later fulfilled RA classification criteria. ^c One RF-patient later fulfilled RA classification criteria, one RF-patient was later diagnosed positive for human parvovirus type B19 infection and one RF+ patient was later diagnosed with dermatomyositis. ^d One patient was not tested for RF.

NA = not applicable; ND = not determined; PAN = polyarteritis nodosa; RF = rheumatoid factor.

Table 3**Approved histology per joint**

Joint	Shoulder	Elbow	Wrist	MCP	PIP	Right knee	Left knee	Ankle	Sum
Procedures (n)	2	7	38	24	3	181	142	11	408
Biopsies approved by histology (%)	0	75	26	25	100	94	94	83	83

MCP = metacarpophalangeal; PIP = proximal interphalangeal.

culty in obtaining appropriate vision within the joint, which led to a practically blind biopsy in many cases.

Creation and evaluation of a method for macroscopic scoring of synovitis during arthroscopy


We used printed photographs of synovitis obtained at arthroscopy in order to evaluate a scoring system that represents a development of a previous scoring procedure [36]. In order to quantitate how individual scorings may differ between different potential arthroscopists, we asked seven raters to assess 50 images. After following the steps outlined above, we analysed a second set of 50 images for intra- and inter-rater variation. Seven raters individually scored 50 images twice (with a minimum of 24 hours in between) for the three parameters, producing a total of 2100 individual scores (700 scores per parameter, 300 scores per rater and 14 scores per image and parameter). Median scores were calculated for all 50 images (Figure 2). Most images scored 1 and 2 in a five point scale (0 to 4, 0 representing no activity and 4 representing maximum activity) indicating low to medium levels of activity. No image rated a maximum median score of 4 for synovitis. More images had median scores of 0 for vascularity and synovitis compared with hypertrophy, indicating fibrotic inactive tissue. Some of these images and scores were used to create the written set of instructions called the Macro-score [see Additional data files 1 and 2].

Intra-rater variation

Intra-rater variation was calculated from all 2100 scores. For hypertrophy 347 of 350 scores (99.1%) scored within one scoring step at the second rating session. For vascularity and synovitis the percentages were 98.9 and 99.1, respectively, showing a very low intra-individual variation. Each rater produced 150 scores, seven images yielded a scoring difference of more than one by one rater, the rest producing a maximum of one point in scoring difference. A mean perfect match (same score twice by the same rater) for hypertrophy was 71%, for vascularity 69% and for synovitis 71% (Figure 3a). When each parameter was analysed per score (Figure 3b), we could see that the best reproducibility was seen at the end points of each index. We could see a drift in consistency (Figure 3c), even though all raters calibrated themselves according to the jointly scored image set immediately before each scoring session.


Inter-rater variation

Inter-rater variation was calculated from the first set of scores by each rater, in all 1050 scores. Of 1050 individual scores, 1036 (98.7%) had an absolute deviation of one point or less from the median score. The deviation from the median varied between raters (Figure 4a); three raters averaged 100%, one rater averaged 99% and two raters averaged 97% of scores deviating by one point or less from the median, respectively, resulting in a mean of 99% of scores within one point of the median. We also analysed inter-rater variation by calculating

Figure 2



Median scores. Scores (%) sorted by median. Fifty images were scored for three parameters twice by seven raters, producing a total of 2100 scores. For S no images had a maximum median score of 4. H = hypertrophy; S = synovitis; V = vascularity.

Figure 3



Intra-rater variation. **(a)** Percentage of perfect matches (score 1 = score 2) for individual raters. **(b)** Percentage of perfect matches (score 1 = score 2) at different scoring levels. **(c)** Rater consistency (sum of score 2 minus score 1). 0 indicates a high consistency between scoring sessions. A positive value indicates an increase in scores at the second scoring session. A negative value indicates a decrease in scores at the second scoring session.

Figure 4



Inter-rater variation. **(a)** Distance to the median. Percentage of scores (from the first rating session) with an absolute distance from the median of one point or less. **(b)** Score range in percentage of total scores. A range of 0 is a perfect match of all seven scores for an image (seven raters). A range of one means that all scores are within two values. H = hypertrophy; S = synovitis; V = vascularity.

the range of scores for each image parameter, given by the seven raters (Figure 4b). Range was two points or less in 139 (92.7%) of 150 image scores. This analysis shows that most scores were indeed close to one another and that raters were in close agreement (+/- one point) for almost all images.


Comparison of control-rater scores to median scores of raters 1 to 7

The same set of 50 images that were scored by raters 1 to 7, were scored by five control-raters (rater A to E) not experienced in arthroscopy using the Macro-score [see Additional data files 1 and 2], producing 150 scores per rater, 650 scores in total. Average individual perfect matches (scores of control-raters equal to median scores of raters 1 to 7) varied between 41% and 56%. Perfect matches of median scores of raters A to E and 1 to 7 gave the best results (Figure 5a), 58% for each parameter, indicating that no individual parameter was harder to score. We also calculated percentage of scores

with an absolute deviation of one point or less from the median score of raters 1 to 7. This turned out to be very high, between 82% and 100%. The average for each control-rater was between 90% and 96%. The median of the control-raters that were within one point of the median for raters 1 to 7 was even better; between 96% and 100%, giving an average of more than 97% of median scores within one point of the median by raters 1 to 7.

Discussion

Arthroscopy in the hands of the orthopaedic surgeons is considered a safe and reliable method. In the surveys by Small [53] and Sherman and colleagues [54] the complication rate was between 2 and 5%. The feasibility and safety of arthroscopy in the hands of rheumatologists have been described in several reports over recent years; Kane and colleagues [55] identified 36 rheumatology centres in Europe, the USA and Australia that performed arthroscopy for clinical and research

Figure 5

Control-rater variation (%). **(a)** Perfect matches (score of raters A to E = median score of raters 1 to 7). *Median score of raters A to E = median score of raters 1 to 7. **(b)** Distance to the median. Scores of raters A to E with an absolute distance from the median of raters 1 to 7 of one point or less (compare with Figure 4a). *Median scores of raters A to E with an absolute distance from the median of raters 1 to 7 of one point or less. H = hypertrophy; S = synovitis; V = vascularity.

purposes. In this survey as well as in reports from individual centres (Table 4) few complications have been reported (1.5%). It is therefore comforting that complications seen in our series are at a low level (0.7%). Haemarthrosis was the most common major complication both from the survey (0.9%), as well as in our study (two patients or 0.5%). Importantly, other major complications, such as joint infection or deep vein thrombosis, did not occur at all in our study. In previous studies joint infections have been observed and been associated with irrigation volume [55], possibly as a marker of the length of the procedure. In our series, no procedure lasted for more than one hour, and we kept lavage volume at a minimum, which might thus contribute to lowering the risk of infection. The use of arthroscopy without tourniquet probably also reduces the risk of thrombosis or thrombophlebitis. In 111 procedures intraarticular steroids were administered in the exam-

ined joint at the end of the procedure, with no increased risk of adverse events.

Despite the use of local anaesthesia, pain may still be a problem. In a study of 50 patients [56] pain was reported in 50% during the procedure, and in 67% postoperatively. In that study, the best results for pain were seen in those who had femoral nerve blocks (most had no pain, and none had moderate or severe pain during or after the procedure) as opposed to local anaesthesia (none reported no pain during the procedure, severe pain was reported in 14% during and 10% after the procedure). Despite this only one patient declined to have a future second arthroscopy. In our study all received local anaesthesia. Occurrence of pain was notified in each case by the physician responsible for the procedure, but not captured in a formal protocol; we had to prematurely terminate the procedure in 3% of cases due to pain during the procedure. Only in one patient was there a severe pain that lasted for two weeks after the procedure. Also, the large majority of patients who were asked to a second arthroscopy consented to this procedure, indicating that the subjective experience of pain was not high. For future arthroscopic investigations, however, we advise that formal protocols for measurement of pain are introduced.

The yield of biopsies was highly satisfactory from the procedures directed towards the knee joints (94%) and acceptable from ankles joints (83%). The yield from small joints was, however, only 34%. This may be an obstacle that is possible to overcome as other groups have reported higher success rates for small joints including metacarpophalangeal joints [57]. As we were not able to reach this level of success, we draw the conclusion that sampling small joints requires special skills and training programs, and that new investigators should be aware of the difficulties. In our case, we decided to restrict the studies mainly to knees in studies where repeated biopsy sampling of the same joint was required [46-48,50,51].

In polyarticular arthritis patients a high degree of clinical inter-articular variation of inflammation between different joints is clinically well recognised. This variation also occurs within the macroscopic and microscopic patterns of the synovium in the individual joint [36,39,58-64]. Some studies point to the correlation of macro and microscopic features [12,36,65-67], while others support that variation is limited [59,60,64,68,69]. To cope with this issue four main principles of sampling the synovium in large joints like the knee have been described: sampling predetermined sites [12]; sampling according to macroscopic signs of inflammation [36]; sampling predetermined sites and according to macroscopic signs of inflammation [65]; and sampling a limited number of predetermined sites to represent the whole joint [58,60,68]. Some studies point to the cartilage pannus junction [36,70,71] as the site of most active inflammation, although not in all aspects [72] implying the special significance of this region. Against this

Table 4**Complications of arthroscopy**

First author	AS (n)	Major (%)	Minor (%)	Haemarthrosis (%)	Joint infection (%)
Sherman and colleagues [54] [‡]	2640	126 (4.8)	97 (3.7)	(2.0)	(<0.5)
Small [53] [‡]	10262		(1.7)	104 (1.0)	21 (0.2)
Szachnowski and colleagues [78]	335	(1.2)	(12.8)	nd	nd
Kuzmanova and colleagues [79]	206	4 (2.0)	15 (7.5)*	7 (3.5)	1 (0.5)
Reece and colleagues [80]	278	1 (0.4)	13 (4.7)	0	1
Wollaston and colleagues [81]	342	1 (0.3)	5 (1.5)	0	0
Smith and colleagues [56]	128		nd (studied pain in conjunction with AS)		
Baeten and colleagues [73]	150	0	(<10)	0	0
Gerlag and Tak [82]	>2000		<0.3		
Kane and colleagues [55]	16532	237 (1.5)		141 (0.9)	16 (0.1)
af Klint (present study)	408	2 (0.5)	1 (0.2)	2 (0.5)	0

[‡]Survey of orthopaedic AS. *Haemarthrosis was regarded as a minor complication. Survey of AS. AS = arthroscopy; nd = not determined.

background, we have chosen to sample tissues based on maximum macroscopic inflammation far from and close to cartilage. When performing consecutive studies with repeated procedures, we prioritised sampling of the biopsies close to the same sites as the first. Samples from the same site are then compared for longitudinal outcome comparisons. To aid in this effort, we have made a simplified map of the knee joint (Figure 1) where macroscopic characteristics and biopsy sites are marked. Each site is also photographically documented by the arthroscope, now digitally stored as opposed to earlier video printer photographs.

There is an obvious need to correlate macroscopic findings and microscopic/molecular analysis of inflamed joints. Several different macroscopic scales have been used [36,65,73] and have been found to correlate with other SM features [12,36,65-67,74,75]. Notably few studies have been published on intra and inter-variation of different raters in macroscopic scoring. This issue was addressed by Reece and colleagues [76] using 44 video recordings of the arthroscopic procedure. Three observers reached good correlation for villous formations, the most pronounced form of hypertrophy, in RA; however, the results were not as good in spondylarthritis patients. Granulations and capillary hyperaemia were not reliable in this study. This is interesting as in the study by Lindblad and Hedfors [36], hyperaemia was the most important feature corresponding to microscopic changes, as also noted by oral surgeons [77]. Before reliable correlations can be made between macro and microscopic scoring systems these parameters need to be studied more extensively. This was one reason for undertaking this study.

In our study we chose not only to score global synovitis, but also to individually measure its main features; hypertrophy and vascularity. Hyperaemia was not included as an individual parameter due to its intrinsic variation physiologically as well as observationally. However, hyperaemia was included in the global synovitis score, in which all observed features of inflammation were included. Thus the score adds more information to the history of the synovitis as a global synovitis score of 0 is not always normal, but also includes previously active fibrotic changes scored as hypertrophy. This score set can be used for scoring entire joints where a video perhaps would be of greater value, but our aim was primarily to get low intra and inter-rater score variation in scoring biopsy sites for research purposes. In this study we report that intra-individual scoring variation was low; at the second scoring 99% of all scores were within one point of the first scores using a five-point scale. Further, a perfect match between first and second scoring sessions was reached in 70% of scores, and no single parameter had a substantially greater intrinsic variability. We also showed low inter-rater variation: 1036 of 1050 individual scores (98.7%) were within one point from the median score. The range was two points or less in 139 of 150 (92.7%) image scores. These numbers could presumably be improved with further training.

We also constructed an easy to use set of instructions for macroscopic evaluation, the Macro-score [see Additional data files 1 and 2]. These written instructions were tested on the same set of 50 photographs by five control-raters with no previous experience of arthroscopy. Without any other directions they scored well; between 41% and 56% of individual scores were equal to the median scores of the raters from the first

group, and between 82% and 100% of scores were not more than one point from the median. The time to understand the score and score 50 images was about 2 to 2.5 hours, suggesting that the Macro-score is reliable and easy to use.

A weakness in this study was the lack of maximal inflammation scores. We presume that this is due to the population studied – we only included chronic polyarthritis patients, and no acute forms such as septic arthritis or gout. Given the clinical activity in these forms of arthritis, we would probably see more active synovitis in such images. At the other end of the spectrum we had a number of images depicting no inflammation, also from healthy individuals serving as controls. Interestingly, also healthy individuals with no history of joint problems could be seen to have minor inflammatory changes, in line with our earlier experience [41].

Conclusions

It is our experience that rheumatological arthroscopy is a safe method with very few complications. For knee joints it is a reliable method to retrieve representative tissue in clinical longitudinal studies. We also created an easy to use macroscopic score that needs to be validated against other methodologies, which we hope will be of value in further developing international standards in this area.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

EaK participated in the design of the study, performed most arthroscopies, collected data from the arthroscopies, participated in designing the Macro-score, scored images, performed the statistical analysis and drafted the manuscript. AC performed arthroscopies, participated in designing the Macro-score, scored images and aided in the statistical analysis. PM, PN and JL performed arthroscopies and scored images. AU participated in the design of the study and scored images. LK participated in the design of the study and helped to draft the manuscript. SL participated in the design of the study, performed arthroscopies, participated in designing the Macro-score, scored images and helped to draft the manuscript. All authors read and approved the final manuscript.

Additional files

The following Additional files are available online:

Additional file 1

A Word file containing a written set of instructions for scoring of synovitis by arthroscopy, images included, called the Macro-score.

See <http://www.biomedcentral.com/content/supplementary/ar2714-S1.doc>

Additional file 2

A Powerpoint file containing calibrating images of synovitis for the Macro-score.

See <http://www.biomedcentral.com/content/supplementary/ar2714-S2.ppt>

Acknowledgements

We would like to express our gratitude to AFA Insurance, the Swedish Rheumatism Association and King Gustaf V's 80-year foundation for financial support of this study. We also thank Marianne Engström, Ola Börjesson, Annika Nordin, Per Larsson, Jöel Kristinn Jöelsson and Anu Lips for valuable help in evaluating synovial images, and Johan Asklung for appreciated statistical advice.

References

- Gibson T, Fagg N, Highton J, Wilton M, Dyson M: **The diagnostic value of synovial biopsy in patients with arthritis of unknown cause.** *Br J Rheumatol* 1985, **24**:232-241.
- Baeten D, Kruithof E, De Rycke L, Boots AM, Mielants H, Veys EM, De Keyser F: **Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy.** *Arthritis Res Ther* 2005, **7**:R359-369.
- Tak PP, Smeets TJ, Daha MR, Kluin PM, Meijers KA, Brand R, Meinders AE, Breedveld FC: **Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity.** *Arthritis Rheum* 1997, **40**:217-225.
- Kraan MC, Versendaal H, Jonker M, Bresnihan B, Post WJ, Hart BA, Breedveld FC, Tak PP: **Asymptomatic synovitis precedes clinically manifest arthritis.** *Arthritis Rheum* 1998, **41**:1481-1488.
- Smeets TJ, Barg EC, Kraan MC, Smith MD, Breedveld FC, Tak PP: **Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis.** *Ann Rheum Dis* 2003, **62**:635-638.
- Baeten D, Demetter P, Cuvelier C, Bosch F Van Den, Kruithof E, Van Damme N, Verbruggen G, Mielants H, Veys EM, De Keyser F: **Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity.** *Ann Rheum Dis* 2000, **59**:945-953.
- Mulherin D, Fitzgerald O, Bresnihan B: **Synovial tissue macrophage populations and articular damage in rheumatoid arthritis.** *Arthritis Rheum* 1996, **39**:115-124.
- Baeten D, Boots AM, Steenbakkers PG, Elewaut D, Bos E, Verheijden GF, Berheijden G, Miltenburg AM, Rijnders AW, Veys EM, De Keyser F: **Human cartilage gp-39+, CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis.** *Arthritis Rheum* 2000, **43**:1233-1243.
- Yanni G, Whelan A, Feighery C, Bresnihan B: **Synovial tissue macrophages and joint erosion in rheumatoid arthritis.** *Ann Rheum Dis* 1994, **53**:39-44.
- Kraan MC, Haringman JJ, Weedon H, Barg EC, Smith MD, Ahern MJ, Smeets TJ, Breedveld FC, Tak PP: **T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis.** *Ann Rheum Dis* 2004, **63**:483-488.
- Smeets TJ, Kraan MC, Versendaal J, Breedveld FC, Tak PP: **Analysis of serial synovial biopsies in patients with rheumatoid arthritis: description of a control group without clinical improvement after treatment with interleukin 10 or placebo.** *J Rheumatol* 1999, **26**:2089-2093.
- Veale DJ, Reece RJ, Parsons W, Radjenovic A, O'Connor PJ, Orgles CS, Berry E, Ridgway JP, Mason U, Boylston AW, Gibbon W, Emery P: **Intra-articular primatised anti-CD4: efficacy in**

- resistant rheumatoid knees. A study of combined arthroscopy, magnetic resonance imaging, and histology. *Ann Rheum Dis* 1999, **58**:342-349.
13. Smeets TJ, Dayer JM, Kraan MC, Versendaal J, Chicheportiche R, Breedveld FC, Tak PP: **The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis.** *Arthritis Rheum* 2000, **43**:270-274.
 14. Kraan MC, Reece RJ, Barg EC, Smeets TJ, Farnell J, Rosenberg R, Veale DJ, Breedveld FC, Emery P, Tak PP: **Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers.** *Arthritis Rheum* 2000, **43**:1820-1830.
 15. Kraan MC, van Kuijk AW, Dinant HJ, Goedkoop AY, Smeets TJ, de Rie MA, Dijkmans BA, Vaishnav AK, Bos JD, Tak PP: **Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis.** *Arthritis Rheum* 2002, **46**:2776-2784.
 16. Gerlag DM, Haringman JJ, Smeets TJ, Zwinderman AH, Kraan MC, Laud PJ, Morgan S, Nash AF, Tak PP: **Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis.** *Arthritis Rheum* 2004, **50**:3783-3791.
 17. Youssef PP, Haynes DR, Triantafillou S, Parker A, Gamble JR, Roberts-Thomson PJ, Ahern MJ, Smith MD: **Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis.** *Arthritis Rheum* 1997, **40**:1400-1408.
 18. Youssef PP, Triantafillou S, Parker A, Coleman M, Roberts-Thomson PJ, Ahern MJ, Smith MD: **Effects of pulse methylprednisolone on cell adhesion molecules in the synovial membrane in rheumatoid arthritis. Reduced E-selectin and intercellular adhesion molecule 1 expression.** *Arthritis Rheum* 1996, **39**:1970-1979.
 19. van Holten J, Pavelka K, Vencovsky J, Stahl H, Rozman B, Genovese M, Kivitz AJ, Alvaro J, Nuki G, Furst DE, Herrero-Beaumont G, McInnes IB, Musick P, Tak PP: **A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis.** *Ann Rheum Dis* 2005, **64**:64-69.
 20. Ulfgren AK, Andersson U, Engstrom M, Klareskog L, Maini RN, Taylor PC: **Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis.** *Arthritis Rheum* 2000, **43**:2391-2396.
 21. Tak PP, Lubbe PA van der, Cauli A, Daha MR, Smeets TJ, Kluijn PM, Meinders AE, Yanni G, Panayi GS, Breedveld FC: **Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis.** *Arthritis Rheum* 1995, **38**:1457-1465.
 22. Cunnane G, Madigan A, Murphy E, FitzGerald O, Bresnihan B: **The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis.** *Rheumatology (Oxford)* 2001, **40**:62-69.
 23. Dolhain RJ, Tak PP, Dijkmans BA, De Kuiper P, Breedveld FC, Miltenburg AM: **Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis.** *Br J Rheumatol* 1998, **37**:502-508.
 24. Tak PP, Taylor PC, Breedveld FC, Smeets TJ, Daha MR, Kluijn PM, Meinders AE, Maini RN: **Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis.** *Arthritis Rheum* 1996, **39**:1077-1081.
 25. Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R, Feldmann M, Maini RN: **Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis.** *Arthritis Rheum* 2000, **43**:38-47.
 26. Smeets TJ, Kraan MC, van Loon ME, Tak PP: **Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue.** *Arthritis Rheum* 2003, **48**:2155-2162.
 27. Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, McInnes IB, Bresnihan B, Tak PP: **Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis.** *Ann Rheum Dis* 2005, **64**:834-838.
 28. Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW, van Laar JM: **Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.** *Arthritis Rheum* 2007, **56**:3909-3918.
 29. Kavanaugh A, Rosengren S, Lee SJ, Hammaker D, Firestein GS, Kalunian K, Wei N, Boyle DL: **Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results.** *Ann Rheum Dis* 2008, **67**:402-408.
 30. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP: **Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response.** *Ann Rheum Dis* 2008, **67**:917-925.
 31. Wijbrandts CA, Dijkgraaf MG, Kraan MC, Vinkenoog M, Smeets TJ, Dinant H, Vos K, Lems WF, Wolbink GJ, Sijpkens D, Dijkmans BA, Tak PP: **The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium.** *Ann Rheum Dis* 2008, **67**:1139-1144.
 32. Wijbrandts CA, Vergunst CE, Haringman JJ, Gerlag DM, Smeets TJ, Tak PP: **Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: Implications for use of synovial sublining macrophages as a biomarker.** *Arthritis Rheum* 2007, **56**:3869-3871.
 33. Haringman JJ, Kraan MC, Smeets TJ, Zwinderman KH, Tak PP: **Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis.** *Ann Rheum Dis* 2003, **62**:715-721.
 34. Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G, Petersen J, Petersen LJ, Beurskens FJ, Schuurman J, Winkel JG van De, Parren PW, Gracie JA, Jongbloed S, Liew FY, McInnes IB: **Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study.** *Arthritis Rheum* 2005, **52**:2686-2692.
 35. Badot V, Galant C, Nzeusseu Toukap A, Theate I, Maudoux AL, Eynde BJ Van den, Durez P, Houssiau FA, Lauwerys BR: **Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis.** *Arthritis Res Ther* 2009, **11**:R57.
 36. Lindblad S, Hedfors E: **Intraarticular variation in synovitis. Local macroscopic and microscopic signs of inflammatory activity are significantly correlated.** *Arthritis Rheum* 1985, **28**:977-986.
 37. Youssef PP, Kraan M, Breedveld F, Bresnihan B, Cassidy N, Cunnane G, Emery P, Fitzgerald O, Kane D, Lindblad S, Reece R, Veale D, Tak PP: **Quantitative microscopic analysis of inflammation in rheumatoid arthritis synovial membrane samples selected at arthroscopy compared with samples obtained blindly by needle biopsy.** *Arthritis Rheum* 1998, **41**:663-669.
 38. Cunnane G, Bjork L, Ulfgren AK, Lindblad S, FitzGerald O, Bresnihan B, Andersson U: **Quantitative analysis of synovial membrane inflammation: a comparison between automated and conventional microscopic measurements.** *Ann Rheum Dis* 1999, **58**:493-499.
 39. Ulfgren AK, Grondal L, Lindblad S, Khademi M, Johnell O, Klareskog L, Andersson U: **Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment.** *Ann Rheum Dis* 2000, **59**:439-447.
 40. Lindblad S, Hedfors E: **Arthroscopic and immunohistologic characterization of knee joint synovitis in osteoarthritis.** *Arthritis Rheum* 1987, **30**:1081-1088.
 41. Lindblad S, Hedfors E: **The synovial membrane of healthy individuals - immunohistochemical overlap with synovitis.** *Clin Exp Immunol* 1987, **69**:41-47.
 42. Lindblad S, Wredmark T: **Traumatic synovitis analysed by arthroscopy and immunohistopathology.** *Br J Rheumatol* 1990, **29**:422-425.
 43. Lindblad S: **Arthroscopic and synovial correlates of pain in osteoarthritis.** *Semin Arthritis Rheum* 1989, **18**(4 Suppl 2):91-93.
 44. Ulfgren AK, Lindblad S, Klareskog L, Andersson J, Andersson U: **Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis.** *Ann Rheum Dis* 1995, **54**:654-661.

45. Catrina AI, Ulfgren AK, Lindblad S, Grondal L, Klareskog L: **Low levels of apoptosis and high FLIP expression in early rheumatoid arthritis synovium.** *Ann Rheum Dis* 2002, **61**:934-936.
46. Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermanson Y, Klareskog L, Ulfgren AK: **Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.** *Arthritis Rheum* 2005, **52**:61-72.
47. af Klint E, Grundtman C, Engstrom M, Catrina AI, Makrygiannakis D, Klareskog L, Andersson U, Ulfgren AK: **Intraarticular glucocorticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vessels.** *Arthritis Rheum* 2005, **52**:3880-3889.
48. Korotkova M, Westman M, Gheorghe KR, af Klint E, Trollmo C, Ulfgren AK, Klareskog L, Jakobsson PJ: **Effects of anti-rheumatic treatments on the prostaglandin E2 biosynthetic pathway.** *Arthritis Rheum* 2005, **52**:3439-3447.
49. Westman M, Korotkova M, af Klint E, Stark A, Audoly LP, Klareskog L, Ulfgren AK, Jakobsson PJ: **Expression of microsomal prostaglandin E synthase 1 in rheumatoid arthritis synovium.** *Arthritis Rheum* 2004, **50**:1774-1780.
50. Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L, Ulfgren AK: **Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.** *Rheumatology (Oxford)* 2002, **41**:484-489.
51. Catrina AI, af Klint E, Ernestam S, Catrina SB, Makrygiannakis D, Botusan IR, Klareskog L, Ulfgren AK: **Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.** *Arthritis Rheum* 2006, **54**:76-81.
52. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al.: **The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.** *Arthritis Rheum* 1988, **31**:315-324.
53. Small NC: **Complications in arthroscopic surgery performed by experienced arthroscopists.** *Arthroscopy* 1988, **4**:215-221.
54. Sherman OH, Fox JM, Snyder SJ, Del Pizzo W, Friedman MJ, Ferkel RD, Lawley MJ: **Arthroscopy – "no-problem surgery". An analysis of complications in two thousand six hundred and forty cases.** *J Bone Joint Surg Am* 1986, **68**:256-265.
55. Kane D, Veale DJ, FitzGerald O, Reece R: **Survey of arthroscopy performed by rheumatologists.** *Rheumatology (Oxford)* 2002, **41**:210-215.
56. Smith MD, Chandran G, Youssef PP, Darby T, Ahern MJ: **Day case knee arthroscopy under regional anaesthesia, performed by rheumatologists.** *Aust N Z J Med* 1996, **26**:108-109.
57. Ostendorf B, Dann P, Wedekind F, Brauckmann U, Friemann J, Koebeke J, Schulitz KP, Schneider M: **Miniarthroscopy of metacarpophalangeal joints in rheumatoid arthritis. Rating of diagnostic value in synovitis staging and efficiency of synovial biopsy.** *J Rheumatol* 1999, **26**:1901-1908.
58. Boyle DL, Rosengren S, Bugbee W, Kavanaugh A, Firestein GS: **Quantitative biomarker analysis of synovial gene expression by real-time PCR.** *Arthritis Res Ther* 2003, **5**:R352-360.
59. Rooney M, Condell D, Quinlan W, Daly L, Whelan A, Feighery C, Bresnihan B: **Analysis of the histologic variation of synovitis in rheumatoid arthritis.** *Arthritis Rheum* 1988, **31**:956-963.
60. Youssef PP, Triantafyllou S, Parker A, Coleman M, Roberts-Thomson PJ, Ahern MJ, Smith MD: **Variability in cytokine and cell adhesion molecule staining in arthroscopic synovial biopsies: quantification using color video image analysis.** *J Rheumatol* 1997, **24**:2291-2298.
61. Crotti TN, Ahern MJ, Lange K, Weedon H, Coleman M, Roberts-Thomson PJ, Haynes DR, Smith MD: **Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: quantification using color video image analysis.** *J Rheumatol* 2003, **30**:2319-2324.
62. Hutton CW, Hinton C, Dieppe PA: **Intra-articular variation of synovial changes in knee arthritis: biopsy study comparing changes in patellofemoral synovium and the medial tibiofemoral synovium.** *Br J Rheumatol* 1987, **26**:5-8.
63. Kirkham B, Portek I, Lee CS, Stavros B, Lenarczyk A, Lassere M, Edmonds J: **Intraarticular variability of synovial membrane histology, immunohistology, and cytokine mRNA expression in patients with rheumatoid arthritis.** *J Rheumatol* 1999, **26**:777-784.
64. Bresnihan B, Cunnane G, Youssef P, Yanni G, Fitzgerald O, Mulherin D: **Microscopic measurement of synovial membrane inflammation in rheumatoid arthritis: proposals for the evaluation of tissue samples by quantitative analysis.** *Br J Rheumatol* 1998, **37**:636-642.
65. Kuzmanova SI, Zaprianov ZN, Solakov PT: **Correlations between arthroscopic findings and synovial membrane histology in patients with rheumatoid synovitis of the knee joint.** *Folia Med (Plovdiv)* 2003, **45**:60-65.
66. Zschabitz A, Neurath M, Grevenstein J, Koepp H, Stofft E: **Correlative histologic and arthroscopic evaluation in rheumatoid knee joints.** *Surg Endosc* 1992, **6**:277-282.
67. Loeuille D, Chary-Valckenaere I, Champigneulle J, Rat AC, Toussaint F, Pinzano-Watrin A, Goebel JC, Mainard D, Blum A, Pourel J, Netter P, Gillet P: **Macroscopic and microscopic features of synovial membrane inflammation in the osteoarthritic knee: correlating magnetic resonance imaging findings with disease severity.** *Arthritis Rheum* 2005, **52**:3492-3501.
68. Dolhain RJ, Ter Haar NT, De Kuiper R, Nieuwenhuis IG, Zwiderman AH, Breedveld FC, Miltenburg AM: **Distribution of T cells and signs of T-cell activation in the rheumatoid joint: implications for semiquantitative comparative histology.** *Br J Rheumatol* 1998, **37**:324-330.
69. Kraan MC, Smith MD, Weedon H, Ahern MJ, Breedveld FC, Tak PP: **Measurement of cytokine and adhesion molecule expression in synovial tissue by digital image analysis.** *Ann Rheum Dis* 2001, **60**:296-298.
70. Rhodes LA, Tan AL, Tanner SF, Radjenovic A, Hensor EM, Reece R, O'Connor P, Emery P, McGonagle D: **Regional variation and differential response to therapy for knee synovitis adjacent to the cartilage-pannus junction and suprapatellar pouch in inflammatory arthritis: implications for pathogenesis and treatment.** *Arthritis Rheum* 2004, **50**:2428-2432.
71. Benito MJ, Murphy E, Murphy EP, Berg WB van den, FitzGerald O, Bresnihan B: **Increased synovial tissue NF-kappa B1 expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis.** *Arthritis Rheum* 2004, **50**:1781-1787.
72. Kane D, Jensen LE, Grehan S, Whitehead AS, Bresnihan B, Fitzgerald O: **Quantitation of metalloproteinase gene expression in rheumatoid and psoriatic arthritis synovial tissue distal and proximal to the cartilage-pannus junction.** *J Rheumatol* 2004, **31**:1274-1280.
73. Baeten D, Bosch F Van den, Elewaut D, Stuer A, Veys EM, De Keyser F: **Needle arthroscopy of the knee with synovial biopsy sampling: technical experience in 150 patients.** *Clin Rheumatol* 1999, **18**:434-441.
74. Yates DB, Scott JT: **Rheumatoid synovitis and joint disease. Relationship between arthroscopic and histological changes.** *Ann Rheum Dis* 1975, **34**:1-6.
75. Ostergaard M, Stoltenberg M, Lovgreen-Nielsen P, Volck B, Jensen CH, Lorenzen I: **Magnetic resonance imaging-determined synovial membrane and joint effusion volumes in rheumatoid arthritis and osteoarthritis: comparison with the macroscopic and microscopic appearance of the synovium.** *Arthritis Rheum* 1997, **40**:1856-1867.
76. Reece RJ, Canete JD, Parsons WJ, Emery P, Veale DJ: **Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis.** *Arthritis Rheum* 1999, **42**:1481-1484.
77. Gynther GW, Holmlund AB, Reinholt FP, Lindblad S: **Temporomandibular joint involvement in generalized osteoarthritis and rheumatoid arthritis: a clinical, arthroscopic, histologic, and immunohistochemical study.** *Int J Oral Maxillofac Surg* 1997, **26**:10-16.
78. Szachnowski P, Wei N, Arnold WJ, Cohen LM: **Complications of office based arthroscopy of the knee.** *J Rheumatol* 1995, **22**:1722-1725.
79. Kuzmanova SI, Atanassov AN, Andreev SA, Solakov PT: **Minor and major complications of arthroscopic synovectomy of the knee joint performed by rheumatologist.** *Folia Med (Plovdiv)* 2003, **45**:55-59.
80. Reece R, Veale D, Kinnon J, Emery P: **Patient safety and tolerability of needle arthroscopy.** *Br J Rheumatol* 1997, **36** Suppl 1:170.

81. Wollaston S, Brion P, Kumar A, Klashman D, Kalunian K: **Complications of knee arthroscopy performed by rheumatologists.** *J Rheumatol* 2001, **28**:1871-1873.
82. Gerlag D, Tak PP: **Synovial biopsy.** *Best Pract Res Clin Rheumatol* 2005, **19**:387-400.